BIOGEN IDEC Inc. is among the world’s largest Biotechnology sector businesses in the world. BIOGEN IDEC Inc.’s employees generate $226.0M in profits on $1.953B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but BIOGEN IDEC Inc. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
BIOGEN IDEC Inc.’s ticker symbol BIIB has recently been trading near $53.43 a share. The BIOGEN IDEC Inc. corporate headquarters in Cambridge, MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $18.282B ensures sufficient liquidity. With a beta of 1.09, the company is more volatile than the market as a whole. When the average equity moves higher, BIOGEN IDEC Inc. moves more aggressively.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment